文献速递咽喉与嗓音

早期注射喉成形术可能降低甲状腺成形术风险:系统评价与Meta分析

Early-injection laryngoplasty may lower risk of thyroplasty: A systematic review and meta-analysis.
PubMed 文献 · Laryngoscope · 2018-01-22

该系统评价与Meta分析旨在确定单侧声带麻痹(UVFP)发病6个月内行注射喉成形术是否降低成人永久性甲状腺成形术率。检索多个数据库后纳入4项队列研究,均为9/9分。275例患者的Meta分析显示,早期注射组行甲状腺成形术的合并相对风险为0.25(95%CI 0.14-0.45),I2为62.4%。结论推荐6个月内提供注射喉成形术(C级证据)。

要点

  • UVFP诊断6个月内行注射喉成形术可降低后续甲状腺成形术风险。
  • 合并相对风险0.25(95%CI 0.14-0.45),基于275例患者4项队列研究。
  • 推荐等级为C级证据,获益大于风险。

核心结论

  • 耳鼻咽喉科医生应为诊断UVFP 6个月内的患者提供注射喉成形术,推荐基于C级证据且获益大于风险。

研究设计与样本

  • 系统评价与Meta分析,检索多个在线研究数据库,纳入随机临床试验和队列研究。
  • 纳入标准为成人UVFP在发病6个月内接受早期注射喉成形术或接受观察者。
  • 最终纳入4项队列研究,共275例患者,采用Newcastle-Ottawa量表评估质量,均为9/9分。
  • 采用随机效应Meta分析计算合并相对风险(RR),用I2统计量评估异质性。

主要发现

  • 早期注射组与保守管理(晚期或无注射)相比,行甲状腺成形术的合并RR为0.25(95%CI 0.14-0.45)。
  • 总体I2为62.4%。

关键数值与推荐

  • 早期注射喉成形术定义为UVFP发病6个月内进行。
  • 主要结局为甲状腺成形术率。
  • 合并RR 0.25(95%CI 0.14-0.45),I2=62.4%。

临床怎么用

  • 对诊断UVFP 6个月内的成人患者,可考虑提供注射喉成形术以降低永久性甲状腺成形术风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether injection laryngoplasty within 6 months following the onset of unilateral vocal fold paralysis (UVFP) decreases the rate of permanent thyroplasty in adults. DATA SOURCES: Search strategies created by a medical librarian were implemented in multiple online research databases. REVIEW METHODS: Inclusion and exclusion criteria were designed to capture randomized clinical trials and cohort studies examining adults with UVFP who received injection laryngoplasty early in the course of treatment, within 6 months of onset, or who were observed. The primary outcome was the rate of thyroplasty. The Newcastle-Ottawa scale was used to assess quality of included cohort studies. Random effects meta-analysis was used to calculate an overall relative risk (RR). Heterogeneity was evaluated with the I2 statistic. RESULTS: The search strategy resulted in 1,177 studies, of which four cohort studies remained for meta-analysis after applying inclusion and exclusion criteria. All studies were rated as 9 of 9 on the Newcastle-Ottawa scale. Meta-analysis of 275 patients with UVFP revealed that the overall pooled RR of undergoing thyroplasty in those receiving an early injection was 0.25 (95% confidence interval 0.14-0.45) compared to conservative management (late or no injection). The I2 overall was 62.4%. CONCLUSION: Otolaryngologists should offer injection laryngoplasty to patients with a diagnosis of UVFP within 6 months of diagnosis (recommendation based on grade C evidence with a preponderance of benefit over harm). Laryngoscope, 128:935-940, 2018.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Vila PM, Bhatt NK, Paniello RC, et al. Early-injection laryngoplasty may lower risk of thyroplasty: A systematic review and meta-analysis. Laryngoscope. 2018. PMID: 29355983. doi:10.1002/lary.26894

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。